Injectable Hypomethylating Agents for Management of Myelodysplastic Syndromes: Patients’ Perspectives on Treatment
Open Access
- 11 September 2021
- journal article
- research article
- Published by Elsevier BV in Clinical Lymphoma Myeloma and Leukemia
- Vol. 22 (3), e185-e198
- https://doi.org/10.1016/j.clml.2021.09.009
Abstract
No abstract availableThis publication has 25 references indexed in Scilit:
- Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: Retrospective analysis of survival after long-term follow-upLeukemia Research, 2015
- Obstacles to adherence to azacitidine administration schedule in outpatient myelodysplastic syndrome and related disordersSupportive Care in Cancer, 2014
- Financial burden experienced by patients undergoing treatment for malignant gliomasNeuro-Oncology Practice, 2014
- Pattern of hypomethylating agents use among elderly patients with myelodysplastic syndromesLeukemia Research, 2011
- Oral treatment of metastatic breast cancer with capecitabine: what influences the decision-making process?European Journal of Cancer Care, 2009
- Valuation of transfusion-free living in MDS: results of health utility interviews with patientsHealth and Quality of Life Outcomes, 2009
- Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): Results of a large internet-based surveyLeukemia Research, 2008
- Patient preference for oral or intravenous chemotherapy: A randomised cross-over trial comparing capecitabine and Nordic fluorouracil/leucovorin in patients with colorectal cancerEuropean Journal of Cancer, 2006
- The Zarit Burden InterviewThe Gerontologist, 2001
- Answering Patients' Needs: Oral Alternatives to Intravenous TherapyThe Oncologist, 2001